In this article, we are going to take a look at where Bristol-Myers Squibb Company (NYSE:BMY) stands against other Friday’s ...

K reports of America’s largest pharmaceutical companies show that they continue to avoid paying much, if any, U.S. corporate income tax.

Two of the most influential voices in strategic communication ? Baron Evans of Sealand and Paul Holmes, will take center stage at the Davos Communications Summit & Awards 2025 on April 10 at the Davos ...

Squibb announced that the European Commission has granted approval to Breyanzi, a CD19-directed chimeric antigen receptor T ...

There’s a lot to be optimistic about in the Healthcare sector as 3 analysts just weighed in on Ascend Wellness Holdings LLC (AAWH – Research ...

The arrival of biosimilars like Celltrion's STEQEYMA and Biocon's YESINTEK is shaking up the psoriatic arthritis market, challenging blockbuster biologics with cost-effective alternatives. As ...

This was the stock's second consecutive day of losses.

Bristol Myers Squibb (BMY) has recently been on Zacks.com's list of the most searched stocks. Therefore, you might want to consider some of the key factors that could influence the stock's performance ...

Emergen Research Logo The increasing prevalence of liver diseases worldwide is a major growth driver in the liver disease therapeutics mark ...

Bristol Myers Squibb’s dividend yield crossed the 4% mark, making it an attractive option for income-focused investors. The ...

BREYANZI has significant market potential due to its innovative approach as a CD19-directed chimeric antigen receptor (CAR) T-cell therapy. The growing prevalence of hematologic malignancies ...

DelveInsight's "TAGRISSO Market Size, Forecast, and Market Insight Report" highlights the details around TAGRISSO, a kinase ...